Neumora Therapeutics (NMRA) Non-Current Debt (2025 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Non-Current Debt of $53.0 million for Q1 2026, down 2.88% quarter-over-quarter from $54.5 million in Q4 2025.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Non-Current Debt (2025 - 2026) Analysis & Trends
Neumora Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $53.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt changed N/A year-over-year to $53.0 million; the TTM figure through Mar 2026 stood at $53.0 million (changed N/A YoY), while the FY2025 annual figure was $54.5 million, changed N/A from the prior year.
- Non-Current Debt for Q1 2026 stood at $53.0 million, down from $54.5 million in the prior quarter.
- The five-year high for Non-Current Debt was $54.5 million in Q4 2025, with the low at $19.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - | 52.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.91 Mn |
| Mar 31, 2026 | 52.96 Mn |
| Dec 31, 2025 | 54.53 Mn |
| Sep 30, 2025 | 19.56 Mn |
| Jun 30, 2025 | 19.45 Mn |